Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
13.84
-0.35 (-2.47%)
At close: Mar 13, 2026, 4:00 PM EDT
13.70
-0.14 (-1.01%)
After-hours: Mar 13, 2026, 7:04 PM EDT
Tenax Therapeutics Employees
As of December 31, 2024, Tenax Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$8,766,500
Market Cap
238.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - | 4 | 2 |
| Dec 31, 2023 | 6 | -2 | -25.00% | 5 | 1 |
| Dec 31, 2022 | 8 | -1 | -11.11% | 7 | 1 |
| Dec 31, 2021 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2020 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 579 |
| ProKidney | 204 |
| Prime Medicine | 146 |
| Ocugen | 116 |
| Theravance Biopharma | 97 |
| Lexicon Pharmaceuticals | 81 |
| AgomAb Therapeutics NV | 58 |
| Jade Biosciences | 55 |
TENX News
- 3 days ago - Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 days ago - Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - Tenax Therapeutics: A Speculative Buy - Seeking Alpha
- 2 months ago - Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
- 3 months ago - Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewsWire
- 3 months ago - Tenax Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript - Seeking Alpha